Dare Bioscience, Inc. Stock News

Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development

Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience's growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs in women's health

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women's health needs, including for women affected by breast cancer The program addresses non-hormonal approaches to women's sexual health which aligns with Daré Bioscience's innovation strategy and development of proprietary Sildenafil Cream, 3.6% Daré Biosc...

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic priorities

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million